EP1212601A1 - Glucose biosensor - Google Patents
Glucose biosensorInfo
- Publication number
- EP1212601A1 EP1212601A1 EP00957741A EP00957741A EP1212601A1 EP 1212601 A1 EP1212601 A1 EP 1212601A1 EP 00957741 A EP00957741 A EP 00957741A EP 00957741 A EP00957741 A EP 00957741A EP 1212601 A1 EP1212601 A1 EP 1212601A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hydrogel
- biosensor
- glucose
- alarm
- pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/06—Investigating concentration of particle suspensions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0031—Implanted circuitry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Definitions
- This invention generally relates to a biosensor for measuring the concentration of glucose molecules in a solution, and more particularly to an implantable glucose monitoring device using a pressure transducer and a glucose sensitive hydrogel having an immobilized glucose binding molecules (GBM), an immobilized charged pendant group, and an immobilized hexose saccharide, the device being proportionally responsive to increases in glucose levels in the physiological fluids such as blood when it is implanted.
- GBM glucose binding molecules
- immobilized charged pendant group an immobilized charged pendant group
- immobilized hexose saccharide the device being proportionally responsive to increases in glucose levels in the physiological fluids such as blood when it is implanted.
- Type II diabetes is one of the major diseases in the United States. In 1995, there were approximately sixteen million Americans suffering from diabetes, including those undiagnosed. It is estimated that 650,000 new cases are diagnosed each year. Diabetes was the seventh leading cause of the death listed on U.S. death certificates in 1993, according to the National Center for Health Statistics. There are two major types of diabetes: type I diabetes (10% of diabetes cases in the United States), and type II diabetes (90 % of diabetes cases in the United States). Type I diabetes is caused by an insulin deficiency due to the destruction of the pancreatic beta cells, and requires daily treatment with insulin to sustain life. Type II diabetes is caused by target organ insulin resistance resulting in a decreased responsiveness to both endogenous and exogenous insulin, and is usually managed by diet and exercise but may require treatment with insulin or other medication. Most people diagnosed with type II diabetes are over 40 years old.
- Insulin is a critical hormone needed to keep glucose concentrations within very narrow physiological limits in normal people though high levels of carbohydrates may be consumed. Not only is insulin secreted by the beta cells of the pancreas, but also its levels are rapidly regulated by glucose concentrations in the blood. Insulin allows the passage of glucose into the targets cells, which contain receptors for uptake of glucose.
- Diabetic patients with an elevated glucose level in the blood, hyperglycemia have either an insulin deficiency or a decreased responsiveness to insulin. Hyperglycemia adversely affects other physiological processes. For example, hyperglycemia causes severe water loss and dehydration.
- Water loss can be so severe that it decreases blood pressure, and the reduced blood pressure may lead to brain damage.
- patients of diabetes are often subject to destructive alterations of other physiological processes, causing blindness, heart attack, stroke, periodontal disease, neuropathy, nephropathy, and atherosclerosis resulting from hyperglycemia.
- Tissue damage can be so extensive that amputations are required to save the patient.
- glucose oxidase GOD
- electrochemical transducers are the most highly developed, and this class of sensors can be further subdivided into potentiometric sensors, conductometric sensors, and amperometric sensors.
- the local pH change due to production of gluconic acid in the GOD reaction can be measured with a pH-selective electrode or an ion selective field effect transistor (ISFET), which is the basis of the potentiometric method.
- ISFET ion selective field effect transistor
- Amperometric sensors must overcome several hurdles before they will ever be useful for commercial in vivo monitoring. Current glucose sensor designs appear unlikely to solve these difficult problems in the near future. The first hurdle arises from electrochemical interference. The analyte (whether hydrogen peroxide or oxygen) must be the only species present which produces a current at the electrode.
- One approach is to use in a hydrogel a chemically immobilized pendant group which is charged at the physiological solution conditions (pH2 to pHIO), a chemically immobilized hexose saccharide such as glucose, galactose, and mannose in the hydrogel, and an immobilized glucose binding molecule (GBM) such as for example, glucokinase, GOD, xylose isomerase, boronic acids, or lectins including isolectin I and Concanabvalin A (Con A) in the hydrogel.
- GBM glucose binding molecule
- lectins including isolectin I and Concanabvalin A (Con A) in the hydrogel.
- the hydrogel swells with increases in glucose concentration using essentially the same physical phenomenon that will be employed in the glucose biosensor, described below.
- the present invention teaches certain benefits in construction and use that will give rise to the objectives described below.
- the hydrogel is in a de-swelled form when there is no free glucose due to the tight binding between Con A and the immobilized glucose or hexose saccharide.
- the hydrogel swells in a proportionto the concentration of free glucose due to competitive binding of the free glucose with the immobilized hexose saccharide to immobilized GBM such as Con A.
- GBM such as Con A.
- the free glucose binds to the GBM, this reduces hydrogel crosslinking density, thereby increasing hydrogel swelling tendency and increasing the pressure exerted by the swelling hydrogel in the enclosure.
- a means for reporting the concentration of the glucose preferably a battery powered telemeter, is operably engaged with the means for measuring, and sends a radio data signal to a receiver operably attached to a computer with an alarm system.
- a primary objective of the present invention is to provide a biosensor having advantages not taught by the prior art.
- Another objective is to provide a biosensor that is extremely sensitive to the concentration of glucose, and also relatively free from interference, even when operating in complex media such as human blood.
- a further objective is to provide a biosensor that directly measures changes in free glucose, rather than the indirect parameters measured by electrodes. This is especially critical in implantable biosensors because this frees the present invention from potential sources of interference as well as alleviates the need for oxygen that is essentially required for the GOD reaction.
- FIGURE 2 is an example of a glucose-containing copolymer
- FIGURE 3 is a side, partial cross-sectional view and diagram of the preferred embodiment of the present invention, showing a biosensor that can be implanted under a diabetic's skin;
- FIGURE 4 is a side partial cross-sectional view of an alternative embodiment thereof, showing a biosensor that is electronically attached to a computer;
- FIGURE 6 is side elevational sectional view of the pressure transducer
- FIGURE 7 is side elevational sectional view of the pressure transducer including the preferred circuit board having miniature diodes, which are part of a diode quad bridge circuit;
- FIGURE 8 is an electrical schematic showing the preferred diode quad bridge circuit
- FIGURE 9 is a block diagram of an automatic alarm system in conjunction with wireless actuation of dialing
- FIGURE 10 is a schematic diagram of a power supply for the various portions of the automatic alarm system
- FIGURE 10 is a schematic diagram of a power supply for the various portions of the automatic alarm system
- FIGURE 11 is a schematic diagram of the signal conditioning circuit
- FIGURE 12 is a schematic diagram of the comparator and control circuit
- FIGURE 14 is a schematic diagram of dialing mechanism
- the structure of the biosensor 10 is provided by an enclosure 20, preferably a cylindrical enclosure 20 having an open end and a closed end.
- the open end is sealed with a semipermeable membrane 26.
- a flexible diaphragm 28 is mounted between the semipermeable membrane 26 and the closed end.
- the hydrogel 30, described below, is enclosed between the semipermeable membrane 26 and the diaphragm 28.
- the enclosure 20 is preferably constructed of a rigid, impermeable, and biocompatible material such as stainless steel; and the enclosure 20 is preferably conjugated with heparin to prevent blood clotting, and polyethylene glycol (PEG) to decrease the body's immune response against the enclosure 20.
- PEG polyethylene glycol
- the semipermeable membrane 26 is permeable to the passage of glucose, and gluconic acid; however, it is impermeable to the passage of blood clots, cells, proteins,lectins, and the hydrogel 30.
- the semipermeable membrane 26 is preferably made of a material rigid enough to sustain the pressure of a swollen glucose sensitive hydrogel 30. If the biosensor 10 is to be implanted into the human body, the semipermeable membrane 26 is preferably an inert, nontoxic material.
- a suitable semipermeable material can be selected from, but is not limited to, the following groups of polymers: cellulose acetate, methyl cellulose, polyvinyl alcohol, and polyurethane.
- the diaphragm 28 is preferably a flexible but conductive material useful for use with a transducer 40. Such diaphragms are known in the art.
- the preferred diaphragm 28 is made of an alloy sold under the trademarks KOVARTM or INVAR 36TM by Hamilton Technology, Inc., of Lancaster, Pennsylvania.
- the diaphragm 28 thickness is preferably approximately 12.5 mm to achieve optimum spot welding and sensitivity. Such a diaphragm is described in Baek SG. Ph.D. Thesis, University of Utah, (1992).
- the diaphragm 28 is preferably seal welded to the enclosure 20 between the semipermeable membrane 26 and the closed end 24 of the enclosure 20.
- the hydrogel 30 fills the chamber within the enclosure 20 between the semipermeable membrane 26 and the diaphragm 28.
- the means for measuring 40 and the means for reporting 60 are located in the chamber within the enclosure 20 between the diaphragm 28 and the closed end 24 of the enclosure 20.
- Con A has been shown to have significant biological properties such as binding of specific saccharides with high affinity.
- Con A containing 238 amino acid residues and having a molecular weight of 27,000, exists as dimers in solution at pH below 6 and as tetramers at physiologic pH.
- the metal ions usually Mn+2 or Ca+2, play an essential role in stabilizing the formation of the specific saccharide binding site.
- the binding properties of Con A to specific saccharides are changed by various conditions such as ionic strength, temperature, and pH.
- Con A shows maximum binding activity to saccharide at pH between 6 to 7.
- Con A alters its binding activity at high pH, above pH 9, due to its conformational changes.
- Tetrameric forms are favored to bind with specific saccharides.
- Con A forms tetramers.
- increasing the temperature 4 °C to 37 °C significantly enhances precipitation of dextran by Con A.
- Con A is denatured above 50 °C like most proteins.
- Con A exists as dimers at lower ionic strength.
- a minimal configurational structure of saccharides such as unmodified hydroxyl groups on the C-3, C-4, and C-6 position in a hexose is essential for binding to Con A with high affinity.
- the binding affinity of a hexose saccharide is dependent upon the configurational factor at C2 hydroxyl group, since mannose with the axial position at C2 hydroxyl group has 40 times higher binding affinity than mannose with the equatorial position at C2 hydroxyl group.
- a vinyl group is preferably attached to C 1 of glucose (allyl glucose; AG) and Con A through etherification reaction of glucose with allyl alcohol and nucleophilic reaction of Con A with metaacryloyl chloride.
- C3, C4, and C6 hydroxyl groups of AG are preferably not modified as described (Obaidat, AA., and Park, K. Pharmaceutical Research 13: 989-995, 1996).
- Copolymerization of AG and modified Con A with cross-linking agents and monomers such as acrylamide and hydroxylethyl methacrylate (HEMA) preferably occurs by a free radical reaction.
- the polymer chain preferably contains glucose and Con A as pendant groups.
- the hydrogel thus formed is preferably porous.
- the porosity is preferably controlled with several methods such as bubbling or excessive addition of powdered salt to the copolymerization reaction.
- the hydrogel preferably swells when free glucose is introduced into the hydrogel due to competitive binding between free glucose with immobilized glucose to immobilized Con A in the hydrogel.
- the swelling ratio is preferably proportional to free glucose concentrations in the solution.
- the reaction ratios of AG and modified Con A, monomer, and cross-linking agents are preferably optimized to give a measurable pressure with a pressure transducer resulting from swelling and de-swelling of the hydrogel due to changing free glucose concentrations.
- p-nitrophenyl-a-D-mannopyranoside and p- nitrophenyl-a-D-glucopyranoside can be used for immobilization on the polymer instead of glucose.
- other GBMs such as GOD, glucokinase, xylose isomerase, boronic acids, and isolactin I can be physically or chemically immobilized on the polymer instead of Con A.
- the biosensor includes a means for measuring 40 the pressure of the hydrogel. This element is critical. While prior art biosensors rely on direct measurement of the GOD catalyzed chemical reaction with an electrode, measurement of the increase in hydrogel pressure and free glucose induced swelling has never been used in the prior art. A biosensor 10 that directly relies on changes in free glucose concentration avoids an important source of outside interference.
- the means for measurement is preferably a pressure transducer 40.
- Pressure transducers are known in the art and those skilled in the field can construct a transducer optimized to the specific needs of the biosensor 10.
- the biosensor 10 can also include a calibration hole 70 which receives a small brass tube 72, a solder stranded copper wire 74, a braided shield 76, insulators 78 and coaxial cables 80.
- the means for measuring 40 is a capaciti ve pressure transducer 40 associated with the flexible diaphragm 28 described above.
- the preferred transducer 40 includes a first electrode 44 and a second electrode 46, the first and second electrodes 44 and 46 being separated by an insulator 48.
- the first and second electrodes 44 and 46, as well as the insulator 48, are coaxially aligned cylinders.
- the flexible diaphragm 28 is preferably welded to the top of the first conductor 44, converting the diaphragm 28 into one of the electrodes of a capacitor portion of the transducer 40.
- the first electrode 44 is connected to the diaphragm 28, and the diaphragm 28 is separated from the second electrode 46 by an air gap 50.
- the diaphragm 28 Since the diaphragm 28 is in mechanical contact with the hydrogel 30, the diaphragm 28 deflects in response to changes in the pressure of the hydrogel 30, thereby changing the size of the air gap 50 between the second electrode 46 and the diaphragm 28, thereby changing the value of the capacitance.
- the value of the capacitance change is detected remotely, preferably using a diode quad bridge circuit 52.
- These pressure transducers 40 have been successfully used to measure pressure changes in flowing polymeric liquids as small as one Pascal. Examples of alternative transducers are described in Takaki, U.S. Pat. No.
- the biosensor 10 includes a means for reporting 60 the concentration of the organic molecule once it has been measured.
- This element will vary greatly depending upon the specific use of the biosensor 10 as well as the needs of the 'user.
- the transducer 40 is simply connected electronically to a computer means, generally a personal computer.
- the computer compares the data from the transducer 40 to a calibration curve to generate usable data for export through a reporting means.
- the computer sounds an alarm if the concentration of the organic molecule exceeds a certain level.
- the computer outputs data onto a reporting outlet such as a computer monitor.
- the computer controls a feedback loop to change a process in response to variation in the concentration of the organic molecule.
- the biosensor 10 is a glucose biosensor 10 that can be implanted into the human body.
- the means for reporting 60 is preferably a battery powered telemeter 60 that transmits a data signal to a receiver operably connected to the computer.
- the computer also compares the data signal to a calibration curve and reports the concentration through a reporting means.
- the reporting means is preferably an audible alarm to warn diabetics if glucose levels get too high or too low.
- the computer also controls an insulin pump to correct the blood glucose level of the diabetic.
- the biosensor 10 would be used on conjunction with an implanted glucose pump and would functionally replace the pancreas in controlling blood glucose levels, allowing diabetics to lead nearly normal lives.
- the invention further includes a method for using a biosensor 10 to measure the concentration of glucose in a solution.
- the method includes the following steps: First, providing a biosensor 10 as described above. Con A is chemically or physically immobilized in the hydrogel 30, preferably using chemical conjugation.
- the biosensor 10 is preferably first immersed in a buffer and inserted into a control solution. The data generated is then compared to a calibration curve to calibrate the biosensor 10. Once the biosensor 10 is removed and rinsed in another buffer, the biosensor 10 is inserted into the solution. The glucose molecules are allowed to diffuse into the polymeric hydrogel 30, causing competitive binding of free glucose with immobilized glucose to Con A.
- the competitive binding between free glucose and immobilized glucose to Con A reduces hydrogel crosslinking, which causes the hydrogel 30 to swell and exert a pressure on the diaphragm 28, as shown in Fig. 5.
- This swelling is measured with the means for measuring 40.
- the means for measuring 40 is preferably a pressure transducer 40.
- the pressure transducer 40 is used to measure the pressure of the hydrogel 30, which is proportional to the concentration of the free glucose level in the hydrogel 30. Data from the transducer 40 regarding this measurement is then sent to a means for reporting 60.
- a battery powered telemeter 60 is used to transmit the data to a computer.
- This can be then reported to the user through a computer monitor, an audible alarm, or a feedback system such as an automatic insulin pump (as described above) or glucagon injection pump.
- a feedback system such as an automatic insulin pump (as described above) or glucagon injection pump.
- the system can be recalibrated by taking blood samples and comparing the glucose readings to those reported by the biosensor 10.
- the computer actuated means of calibration can then be adjusted to correct for any errors.
- the output of a sensor is always monitored and compared with a preset value (or threshold value). If the sensor output is out of the preset range, an alarm signal is generated. This alarm signal can be further utilized to actuate a certain alarm protocol such as automatic dialing and send a prerecorded message corresponding to the condition detected.
- a preset value or threshold value
- the block diagram in Figure 9 shows a diagram of a working model for giving an alarm to diabetics and a signal to caretakers using automatic dialing and sending of a prerecorded message when blood glucose levels drop to the level of hypoglycemia.
- the major elements of an automatic alarm device are a power supply 100, a sensor (such as biosensor 10 or other sensor for monitoring a physiological condition), a signal conditioning circuit 104, a comparator circuit 108, a transmitter/receiver 112a and 112b, a dial actuator 116, and a control circuit.
- the power supply 100 preferably provides electric energy to all the elements of the device requiring power. Considering portability of the device, a dry-cell battery is the preferred choice for supplying power. However, compatibility of the cell with power requirements of all the elements (voltage and capacity) will be somewhat determinative of the type used. As presently perceived, a large capacity 9-volt battery is believed to be the best choice.
- a bipolar power supply using 2 batteries makes the circuit design much easier.
- a low -battery indicator should be an essential part.
- the need for the signal conditioning circuit 104 depends on the quality of the signal from the sensor. If the sensor signal comes along with a great deal of environmental noise, the signal conditioning circuit 104( Figure 11) is necessary to operate the device in a reliable manner.
- a high input-impedance differential amplifier works for any kind of sensor.
- a prepackaged circuit, the so- called “instrumentation amplifier” is commercially available.
- a quad-op amp IC e.g., LM 384 from National Semiconductors
- a differential amplifier is excellent in removing common mode noise.
- the gain of the differential amplifier can be adjusted to provide signals of a good linear range.
- a low-pass filter after differential amplification will further decrease high frequency noise.
- An RC time constant of 0.1 to 1 seconds is appropriate. For example, an RC time constant of 1 second can be obtained using 100 kohm and lOmF Comparator and Control Circuit.
- a comparator always compares the monitored signal (here, from the output of the signal conditioning circuit) with the preset value.
- the threshold value will be adjusted using a potentiometer. If the monitored signal goes over the threshold value, the output of the comparator changes its status from '0' to '1' or from 'off to 'on'. This change of status is utilized to actuate a following digital circuit.
- the simplest circuit will be driving an electromechanical switch to 'on' position, by which a transmitter circuit is connected to the power supply; LM311 type comparator should best fit the purpose.
- the comparator circuit 108 must be with extra control circuits 130 ( Figure
- the extra controls are for deactivating the device and resetting the device in the case when alarms are sent mistakenly or by device malfunction. Furthermore, an extra switch should be there to actuate dialing in any case at the discretion of the device user. All these factors can be achieved by using a digital D-flip-flop IC(C7474)
- the comparator circuit 108 can be used for determining if the sensor 10 operates normally as well as for alarming. If sensor output goes beyond an expected operating range including an alert level, the comparator 108 will indicate malfunction of the sensor 10.
- a Transmitter/receiver 112a and 112b is necessary in order to operate a phone 114 at a distance from the device-carrier ( Figure 13). Wireless activation of the phone 114 can be achieved using a typical FM method.
- a transmitter consists of a carrier wave generator 140, a signal generator 144, a modulator 148 to mix signal to carrier wave, a power booster 152, and a radiator 156.
- the carrier wave frequency may be in the range of several tens to several hundreds megahertz.
- the signal must be unique that the receiver picks up to avoid mistaken dialing due to environmental noises from other electronic devices.
- a receiver 112b operates in a reversed manner to that of a transmitter 112a. Although a transmitter/receiver, 112a/l 12b must be custom designed eventually, it can be adapted from a minimally modified transmitter/receiver used in kids' remote control toys.
- Dialing to a remote alarm signal can be achieved in a number of ways that will be well known to those skilled in the art.
- a schematic of such a system is shown in FIG. 14 and those familiar with remote telephone interactions will be familiar with numerous ways of implementing this and other configurations.
- the alarm system can also function as a system for treating hypoglycemia in a diabetic.
- FIG. 15 there is shown a schematic of an alarm system similar to that shown in FIG. 9.
- the system further includes, however, an injection mechanism 150 that dispenses glucose, another sugar, or a drug into the blood stream of the patient in response to the alarm.
- the injection device 150 may provide predetermined dose, or may inject varying quantities in response to the physiological condition detected by the sensor 10.
- the injection device 150 may be hard wired to the system, or may be controlled by the transmitter 112a.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15103499P | 1999-08-27 | 1999-08-27 | |
US151034P | 1999-08-27 | ||
PCT/US2000/023194 WO2001016575A1 (en) | 1999-08-27 | 2000-08-23 | Glucose biosensor |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1212601A1 true EP1212601A1 (en) | 2002-06-12 |
EP1212601A4 EP1212601A4 (en) | 2006-03-29 |
Family
ID=22537059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00957741A Withdrawn EP1212601A4 (en) | 1999-08-27 | 2000-08-23 | Glucose biosensor |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1212601A4 (en) |
JP (1) | JP2003517588A (en) |
KR (1) | KR100771711B1 (en) |
AU (1) | AU6931500A (en) |
WO (1) | WO2001016575A1 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004507283A (en) * | 2000-04-22 | 2004-03-11 | エム−バイオテック インコーポレイテッド | Hydrogel biosensor and health alarm system based on biosensor (HYDROGELBIOSENSORANDBIOENSENSOR-BASEDHEALTHALARMSYSTEM) |
GB0116860D0 (en) * | 2001-07-10 | 2001-09-05 | Univ Montfort | Gel compositions |
AUPR808001A0 (en) | 2001-10-05 | 2001-10-25 | Ragless, Clive Lindsay | Method and apparatus for determining concentration of a chemical substance in a solution |
US20030153026A1 (en) * | 2002-01-04 | 2003-08-14 | Javier Alarcon | Entrapped binding protein as biosensors |
US7004928B2 (en) | 2002-02-08 | 2006-02-28 | Rosedale Medical, Inc. | Autonomous, ambulatory analyte monitor or drug delivery device |
US7052652B2 (en) | 2003-03-24 | 2006-05-30 | Rosedale Medical, Inc. | Analyte concentration detection devices and methods |
JP4799557B2 (en) | 2004-06-09 | 2011-10-26 | ベクトン・ディキンソン・アンド・カンパニー | Multi-sample sensor |
GB2426333A (en) * | 2005-01-20 | 2006-11-22 | Mark Christopher Turpin | Sensor device for the measurement of concentration in liquid mixtures |
US20060281187A1 (en) | 2005-06-13 | 2006-12-14 | Rosedale Medical, Inc. | Analyte detection devices and methods with hematocrit/volume correction and feedback control |
WO2007041244A2 (en) | 2005-09-30 | 2007-04-12 | Intuity Medical, Inc. | Multi-site body fluid sampling and analysis cartridge |
US8801631B2 (en) | 2005-09-30 | 2014-08-12 | Intuity Medical, Inc. | Devices and methods for facilitating fluid transport |
FR2909292B1 (en) * | 2006-12-04 | 2009-01-30 | Univ Grenoble 1 | METHOD AND DEVICE FOR VARYING THE pH OF A SOLUTION |
EP1977687A1 (en) | 2007-04-05 | 2008-10-08 | Koninklijke Philips Electronics N.V. | Hydrogel based device for detecting an environmental state |
EP2293719B1 (en) | 2008-05-30 | 2015-09-09 | Intuity Medical, Inc. | Body fluid sampling device -- sampling site interface |
CA2726067C (en) | 2008-06-06 | 2020-10-20 | Intuity Medical, Inc. | Detection meter and mode of operation |
US10383556B2 (en) | 2008-06-06 | 2019-08-20 | Intuity Medical, Inc. | Medical diagnostic devices and methods |
WO2010047799A1 (en) * | 2008-10-22 | 2010-04-29 | Surmodics, Inc. | Swellable biodegradable polymeric matrices and methods |
KR101135624B1 (en) | 2009-01-15 | 2012-04-17 | 한양대학교 산학협력단 | A biosensor coated with electroactive polymer layer for extension of biosensor life span |
KR101065748B1 (en) | 2009-03-17 | 2011-09-19 | 한양대학교 산학협력단 | A biosensor coated with electroactive polymer layer showing bending behavior |
US8919605B2 (en) | 2009-11-30 | 2014-12-30 | Intuity Medical, Inc. | Calibration material delivery devices and methods |
US9151764B2 (en) | 2010-02-16 | 2015-10-06 | Lightship Medical Limited | Barrier layer for glucose sensor |
JP5696961B2 (en) * | 2010-05-26 | 2015-04-08 | 独立行政法人物質・材料研究機構 | Sugar-responsive gel and drug administration device |
WO2011162823A1 (en) | 2010-06-25 | 2011-12-29 | Intuity Medical, Inc. | Analyte monitoring methods and systems |
EP2652510B1 (en) * | 2010-12-17 | 2016-06-22 | EyeSense AG | Use of hydrogels for biosensors having elevated sensitivity |
CN107029245A (en) * | 2011-03-02 | 2017-08-11 | 森苏林公司 | Vesicle |
EP3750480B1 (en) | 2011-08-03 | 2022-02-02 | Intuity Medical, Inc. | Body fluid sampling arrangement |
WO2013081363A1 (en) * | 2011-11-28 | 2013-06-06 | 에스디 바이오센서 주식회사 | Biosensor for measuring glycosylated haemoglobin using potentiometry |
WO2014190230A1 (en) | 2013-05-23 | 2014-11-27 | Iphenotype Llc | Phenotypic integrated social search database and method |
WO2014205412A1 (en) | 2013-06-21 | 2014-12-24 | Intuity Medical, Inc. | Analyte monitoring system with audible feedback |
DE102013212539B4 (en) * | 2013-06-27 | 2015-07-23 | Carl Von Ossietzky Universität Oldenburg | Method and apparatus for analysis |
KR101783695B1 (en) * | 2015-10-02 | 2017-10-11 | 주식회사 엔게인 | Polyhydroxyethylmethacrylate based hydrogel, method for preparing the same and glucose sensor comprising the same |
WO2019118231A1 (en) * | 2017-12-11 | 2019-06-20 | Microoptx Inc. | Implantable ocular glucose sensor devices and methods |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5544651A (en) * | 1992-09-08 | 1996-08-13 | Wilk; Peter J. | Medical system and associated method for automatic treatment |
EP0846440A2 (en) * | 1996-12-05 | 1998-06-10 | Sarcos, Inc. | System for remote monitoring of personnel |
US5771001A (en) * | 1996-11-18 | 1998-06-23 | Cobb; Marlon J. | Personal alarm system |
US5830506A (en) * | 1992-01-10 | 1998-11-03 | De Montfort University | Method of making a reversible gel drug delivery vehicle |
WO1999017095A1 (en) * | 1997-09-30 | 1999-04-08 | M-Biotech, Inc. | Biosensor |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1327838C (en) * | 1988-06-13 | 1994-03-15 | Fred Zacouto | Implantable device to prevent blood clotting disorders |
US5995860A (en) * | 1995-07-06 | 1999-11-30 | Thomas Jefferson University | Implantable sensor and system for measurement and control of blood constituent levels |
US6030827A (en) * | 1998-01-23 | 2000-02-29 | I-Stat Corporation | Microfabricated aperture-based sensor |
-
2000
- 2000-08-23 JP JP2001520081A patent/JP2003517588A/en active Pending
- 2000-08-23 WO PCT/US2000/023194 patent/WO2001016575A1/en active Application Filing
- 2000-08-23 AU AU69315/00A patent/AU6931500A/en not_active Abandoned
- 2000-08-23 EP EP00957741A patent/EP1212601A4/en not_active Withdrawn
- 2000-08-23 KR KR1020027002620A patent/KR100771711B1/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830506A (en) * | 1992-01-10 | 1998-11-03 | De Montfort University | Method of making a reversible gel drug delivery vehicle |
US5544651A (en) * | 1992-09-08 | 1996-08-13 | Wilk; Peter J. | Medical system and associated method for automatic treatment |
US5771001A (en) * | 1996-11-18 | 1998-06-23 | Cobb; Marlon J. | Personal alarm system |
EP0846440A2 (en) * | 1996-12-05 | 1998-06-10 | Sarcos, Inc. | System for remote monitoring of personnel |
WO1999017095A1 (en) * | 1997-09-30 | 1999-04-08 | M-Biotech, Inc. | Biosensor |
Non-Patent Citations (7)
Title |
---|
LEE S J ET AL: "SYNTHESIS AND CHARACTERIZATION OF SOL-GEL PHASE-REVERSIBLE HYDROGELS SENSITIVE TO GLUCOSE" JOURNAL OF MOLECULAR RECOGNITION, HEYDEN & SON LTD., LONDON, GB, vol. 9, no. 5/6, 1996, pages 549-557, XP009012205 ISSN: 0952-3499 * |
NAKAMAE KATSUHIKO ET AL: "Formation of poly(glucosyloxyethyl methacrylate): Concanavalin A complex and its glucose-sensitivity" JOURNAL OF BIOMATERIALS SCIENCE POLYMER EDITION, vol. 6, no. 1, 1994, pages 79-90, XP009050559 ISSN: 0920-5063 * |
OBAIDAT A A ET AL: "CHARACTERIZATION OF GLUCOSE DEPENDENT GEL-SOL PHASE TRANSITION OF THE POLYERMIC GLUCOSE-CONCANAVALIN A HYDROGEL SYSTEM" PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 13, no. 7, 1996, pages 989-995, XP009012206 ISSN: 0724-8741 * |
OBAIDAT A A ET AL: "Characterization of protein release through glucose-sensitive hydrogel membranes" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 18, no. 11, June 1997 (1997-06), pages 801-806, XP004063905 ISSN: 0142-9612 * |
See also references of WO0116575A1 * |
TANNA S ET AL: "CHARACTERIZATION OF MODEL SOLUTE AND INSULIN DELIVERY ACROSS COVALENTLY MODIFIED LECTIN-POLYSACCHARIDE GELS SENSITIVE TO GLUCOSE" ARCHIVES OF DERMATOLOGICAL RESEARCH, SPRINGER, INTERNATIONAL, BERLIN, DE, vol. 4, no. 2, 1998, pages 117-122, XP009012222 ISSN: 0340-3696 * |
WEATHERMAN ROSS V ET AL: "Specificity of C-Glycoside complexation by Mannose/Glucose specific lectins" BIOCHEMISTRY, vol. 35, no. 11, 1996, pages 3619-3624, XP002335712 ISSN: 0006-2960 * |
Also Published As
Publication number | Publication date |
---|---|
JP2003517588A (en) | 2003-05-27 |
WO2001016575A1 (en) | 2001-03-08 |
AU6931500A (en) | 2001-03-26 |
KR100771711B1 (en) | 2007-10-30 |
EP1212601A4 (en) | 2006-03-29 |
KR20020035583A (en) | 2002-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6475750B1 (en) | Glucose biosensor | |
EP1212601A1 (en) | Glucose biosensor | |
US6268161B1 (en) | Biosensor | |
JP4124827B2 (en) | Apparatus and method for measuring an analyte level | |
US10039480B2 (en) | Membrane for use with implantable devices | |
US6558321B1 (en) | Systems and methods for remote monitoring and modulation of medical devices | |
US6741877B1 (en) | Device and method for determining analyte levels | |
WO2001081890A2 (en) | Hydrogel biosensor and biosensor-based health alarm system | |
Han et al. | Biosensor | |
Guenther et al. | Hydrogel-based piezoresistive biochemical microsensors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020327 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7G 01N 33/66 B Ipc: 7G 01N 33/53 B Ipc: 7C 12M 1/34 B Ipc: 7A 61K 9/22 B Ipc: 7G 01N 15/06 A Ipc: 7G 01N 33/487 B Ipc: 7A 61B 5/00 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060214 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20071228 |